

What Every Practitioner Should Know About the Current Vaccination Campaign

Col. Arden Andersen, MSPH, PhD, DO
Hollie Resseguie, PharmD

1

Objectives

- At the conclusion of this presentation, the attendee will be able to
 - Identify current vaccine schedule recommendations and know where to find them
 - List current vaccine constituents
 - Describe the role of common constituents
 - Recognize the difference between historical and current vaccines and vaccination schedules

2

What This Presentation IS and IS NOT

- IS
 - Report of current common vaccination recommendations
 - Static
- IS NOT
 - Replacement for individualized medical advice
 - Comprehensive of all vaccines and recommendations
 - A guide for vaccine storage and administration

3

Conflict of Interest Statement

- The speakers have no conflict of interest to disclose

4

Hollie Resseguie

- Kansas State University 2004, Bachelors of Music Education
- University of Kansas School of Pharmacy 2016, Bachelor's of Pharmaceutical Science, Doctor of Pharmacy
- Director of Pharmacy, O'Brien Pharmacy

5

Vaccines

Taboo:
Religion, Politics

6

Vocabulary

- Adjuvant—A substance, distinct from antigen, that enhances T cell activation by promoting the accumulation of antigen-presenting cells at a site of antigen exposure and by enhancing the expression of costimulators and cytokines by the antigen-presenting cells¹
- Antibody—A type of glycoprotein molecule, also called immunoglobulin (Ig), produced by B lymphocytes, that bind antigens, often with a high degree of specificity and high affinity¹
- Antigen—A molecule that binds to an antibody or a T cell antigen receptor (TCR). Antigens that bind to antibodies include all classes of molecules. Most TCRs bind only to peptide fragments of proteins complexed with major histocompatibility molecules; both the peptide ligand and the native protein from which it is derived are called T cell antigens¹
- Excipient = constituent = component

7

Vocabulary

- Immunity—resistance to disease, specifically infectious disease¹
- Vaccine—A preparation of microbial antigen, often combined with adjuvants, that is administered to individuals to induce protective immunity against microbial infections. The antigen may be in the form of live but avirulent microorganisms, killed microorganisms, or purified macromolecular components of microorganisms¹
- Vaccination vs. Immunization
 - “You can be vaccinated but if there is no immunity, you are not immunized. You can be unvaccinated, but if you have had the disease and have protection, you are immune; therefore you are immunized.”²

8

Antigen Types

- Live attenuated vaccine
- Inactivated vaccine
 - Whole cell
 - Fractional
 - Polysaccharide
 - Subunit
 - Toxoid
 - Conjugated polysaccharide

9

Who Makes Vaccine Recommendations?

- Advisory Committee on Immunization Practices (ACIP)
 - United States Federal Government agency that advises Centers for Disease Control and Prevention (CDC)
- CDC ultimately makes recommendations published in Morbidity and Mortality Weekly Report (MMWR)
- CDC publishes Epidemiology and Prevention of Vaccine-Preventable Diseases "Pink Book"
 - All official vaccine information and recommendations

10

CDC-Recommended Provider Behavior

11

Immunization Strategies for Healthcare Practices and Providers³

- CDC recommendations for healthcare provider behavior regarding vaccines
- Levels of disease are "late indicators" of soundness of immunization SYSTEM
 - "Greater understanding of strategies to increase and sustain immunization levels is necessary in order to create lasting, effective immunization delivery system."
- AFIX—recommended by government and non-government vaccine programs and medical professional societies

12

AFIX³

- Assessment of immunization coverage of public and private providers
 - CDC-developed software that electronically assesses medical records
- Feedback of diagnostic information to improve service delivery
- Incentives to motivate providers to change immunization practices or recognition of improved or high performances
- exchange of information among providers
- “Does NOT attempt to persuade clients to be vaccinated, but instead focuses on changing healthcare provider behavior”


13

Federal Programs Regarding Vaccine Rates

- Vaccines for Children (VFC)—federal funding to purchase vaccines to make them available at no cost to those who meet income and eligibility requirements
 - www.cdc.gov/vaccines/programs/vfc/default.htm
- Immunization Information System (IIS)
 - Optional database to keep individual vaccine records
 - cdc.gov/vaccines/programs/iis/index.html


14

Brief Review of the Immune System




15

Brief Review of the Immune System




16

Brief Review of the Immune System



17

Two Ways to Confer Immunity



18

Vaccines: Miracle or Scary? And Why?

19

Vaccines—Miracle?

- CDC lists vaccines as great public health achievement of 20th century
- Curing an illness helps that person, preventing it helps everyone
- Herd immunity protects those unable to be vaccinated
 - Vaccine mandates scare some, vaccine choice scares some
 - "Recent outbreaks show that even vaccinated people are at risk for disease if there is not adequate vaccine coverage for a population"³

20

Vaccines—Miracle?³

- Vaccine Injury Compensation Program
 - Vaccine Adverse Event Reporting System (VAERS)
 - Anyone can report
 - Available at vaers.hhs.gov or wonder.cdc.gov/vaers
 - Number of reports ~28,000/year
 - Number of vaccines given ~10 million/year³
- Vaccine Safety Datalink
 - 10 large managed care organizations gather data on those vaccinated at their sites allowing for planned safety studies and timely investigations
 - <http://cdc.gov/vaccinationsafety/vsd>

21

Vaccines—Miracle?³

- Clinical Immunization Safety Assessment Network
 - Resource for practitioners to manage individual patients with vaccine related side effects
 - <http://cdc.gov/vaccinesafety/Activities/cisa.html>
 - Vaccine Analytic Unit
 - Monitors safety of vaccines given to military
 - CDC and DoD
 - Study vaccines infrequently used in general population
 - Currently studying specific vaccine potential adverse effects regarding autoimmune thyroid disease and Guillain-Barré syndrome (GBS)

22

Vaccines—Miracle?³

- National Childhood Vaccine Injury Act and National Vaccine Injury Compensation Program
 - Diphtheria/Tetanus/Pertussis claims paid despite no scientific evidence of causation
 - Manufacturers disincentivized from making vaccines
 - Vaccine cost went up
 - Availability went down
 - Health care officials got worried
 - No fault program
 - Don't have to prove negligence
 - Compensates for certain events following a vaccine
 - Covers all childhood vaccines and those vaccines if administered to an adult and a certain list of events following them

23

Vaccines—Miracle?

- Vaccine Injury Table
 - www.hrsa.gov/vaccinecompensation/vaccineinjurytable.pdf

Vaccine	Illness, disability, injury or condition covered	Time period for first symptom or manifestation of onset or of significant aggravation after vaccine administration
I. Vaccines containing tetanus toxoid (e.g., DTaP, DTP, DT, Td, or TT)	1.Anaphylaxis 2.Brachial Neuritis 3.Shoulder Injury Related to Vaccine Administration 4.Vasovagal syncope	<4 hours 2-28 days (not less than 2 days and not more than 28 days) <48 hours <1 hour
II. Vaccines containing whole cell pertussis bacteria, extracted or partial cell pertussis bacteria, or specific pertussis antigens (e.g., DTP, DTaP, P, DTP-10b)	1.Anaphylaxis 2.Encephalopathy or encephalitis 3.Shoulder Injury Related to Vaccine Administration 4.Vasovagal syncope	<4 hours <72 hours <48 hours <1 hour

24

Vaccines—Miracle?

- Countermeasures Injury Compensation Program
 - Like above but for vaccines/treatments administered in preventative situations—flu pandemic, anthrax, etc
 - Includes those given to military personnel
- Vaccine Information Statements given prior to any vaccine
 - cdc.gov/vaccines/pubs/vis or immunize.org
- Confirmation bias

25

Vaccines--Scary?

- Confirmation bias
- As preventable diseases have become less common, fear of vaccine as become more common
 - 28,000 reports of vaccine adverse reactions/effects each year
 - More people know someone believed to have an adverse effect than on of the preventable diseases³
- Giving a healthy patient a drug—higher standard of safety expected to maintain public confidence
 - Given to infants—very low tolerance for any adverse events
 - Widespread vaccine use means and adverse event could affect many people

26

Vaccines--Scary?

- “Hi-jacking” immune system by bypassing cell-mediated immunity and provoking immunity
 - Linked by some to increasing autoimmunity⁴
- Distrust of the medical community
 - Changing recommendations (fat, cholesterol)
 - Vaccines and drugs withdrawn from market
- Seemingly contradictory vaccine recommendations
 - Hepatitis B, polio

27

Vaccines--Scary?

- Vaccine or living conditions?
- Vaccine invented vs. in use
- Changing definition of diseases

28

Vaccines--Scary?

- Vaccines for diseases that “aren’t severe” or “aren’t likely”
 - Chicken pox, shingles, hepatitis B
- Vaccines causing further illness
 - Varicella → shingles⁵
 - Pneumococcal strain replacement^{3,5}

29

Vaccines--Scary?

- What’s in it?
- “It’s SO many these days”

30



VACCINES
PROVOKE
WHICH PART
OF THE
IMMUNE
SYSTEM?

Humoral

31

Vaccine Schedule History

32

Vaccine Schedule History⁶

- By mid-1980's 7 vaccines were available
 - Children received 5 shots by age 2 and not more than 1 at a single visit
- Now as many as 27 shots by age 2 and 5 per visit

33

1989	DTP	2019	Childhood	Adolescent
	MMR		DTaP	Tdap
	Polio	MMR	Polio	HPV
	Hib	Hib	Hib	Meningococcal conjugate
	• 8 vaccines in 4 shots	Hep B	Hep B	Influenza
		Varicella	Varicella	Meningococcal B
		Hep A	Hep A	Adult
		Pneumococcal	Pneumococcal	Influenza
		Influenza	Influenza	Tdap
		Rotavirus	Rotavirus	Shingles
		14 vaccines in 10 shots plus boosters		Pneumococcal

34



WHO PUBLISHES OFFICIAL VACCINE RECOMMENDATIONS AND INFORMATION?

The CDC

<http://www.innomind.org>


35

Current Vaccine Schedules and Recommendations




Vaccine	Age Range
Influenza	65 years and older
Tdap	11-12 years, 15-64 years, 65 years and older
MMR	11-12 years
MMR2	11-12 years
MMR3	11-12 years
MMR4	11-12 years
MMR5	11-12 years
MMR6	11-12 years
MMR7	11-12 years
MMR8	11-12 years
MMR9	11-12 years
MMR10	11-12 years
MMR11	11-12 years
MMR12	11-12 years
MMR13	11-12 years
MMR14	11-12 years
MMR15	11-12 years
MMR16	11-12 years
MMR17	11-12 years
MMR18	11-12 years
MMR19	11-12 years
MMR20	11-12 years
MMR21	11-12 years
MMR22	11-12 years
MMR23	11-12 years
MMR24	11-12 years
MMR25	11-12 years
MMR26	11-12 years
MMR27	11-12 years
MMR28	11-12 years
MMR29	11-12 years
MMR30	11-12 years
MMR31	11-12 years
MMR32	11-12 years
MMR33	11-12 years
MMR34	11-12 years
MMR35	11-12 years
MMR36	11-12 years
MMR37	11-12 years
MMR38	11-12 years
MMR39	11-12 years
MMR40	11-12 years
MMR41	11-12 years
MMR42	11-12 years
MMR43	11-12 years
MMR44	11-12 years
MMR45	11-12 years
MMR46	11-12 years
MMR47	11-12 years
MMR48	11-12 years
MMR49	11-12 years
MMR50	11-12 years
MMR51	11-12 years
MMR52	11-12 years
MMR53	11-12 years
MMR54	11-12 years
MMR55	11-12 years
MMR56	11-12 years
MMR57	11-12 years
MMR58	11-12 years
MMR59	11-12 years
MMR60	11-12 years
MMR61	11-12 years
MMR62	11-12 years
MMR63	11-12 years
MMR64	11-12 years
MMR65	11-12 years
MMR66	11-12 years
MMR67	11-12 years
MMR68	11-12 years
MMR69	11-12 years
MMR70	11-12 years
MMR71	11-12 years
MMR72	11-12 years
MMR73	11-12 years
MMR74	11-12 years
MMR75	11-12 years
MMR76	11-12 years
MMR77	11-12 years
MMR78	11-12 years
MMR79	11-12 years
MMR80	11-12 years
MMR81	11-12 years
MMR82	11-12 years
MMR83	11-12 years
MMR84	11-12 years
MMR85	11-12 years
MMR86	11-12 years
MMR87	11-12 years
MMR88	11-12 years
MMR89	11-12 years
MMR90	11-12 years
MMR91	11-12 years
MMR92	11-12 years
MMR93	11-12 years
MMR94	11-12 years
MMR95	11-12 years
MMR96	11-12 years
MMR97	11-12 years
MMR98	11-12 years
MMR99	11-12 years
MMR100	11-12 years

36



40

Current Vaccine Schedule

41

Diphtheria/Tetanus/Pertussis--Vaccine³

- *Diphtheria, tetanus, whole-cell pertussis (DTP)*
 - *No longer used in US*
- Primary vaccine pediatric: diphtheria, tetanus toxoids, acellular pertussis (DTaP)
- Primary vaccine pediatric: diphtheria, tetanus (DT)
- Booster: reduced diphtheria, tetanus (Td)
- Booster adult: reduced diphtheria, tetanus, acellular pertussis (Tdap)
- Also available combined with inactivated polio or inactivated polio and *Haemophilus influenzae* type B

42

Diphtheria/Tetanus/Pertussis--Schedule³

- **Childhood**
 - DTaP
 - 5 dose series at 2,4,6, 15-18 months, 4-6 years
- **Adolescent**
 - Tdap
 - 1 dose at 11-18 years once full series of DTaP is completed
- **Adult**
 - Tdap—1 dose, then
 - Td—every 10 years
 - Pregnancy
 - 1 dose Tdap each pregnancy regardless of number of pregnancies, spacing, etc.

43

Contraindications, Precautions, Adverse Events and Reactions

Contraindication (CI)	<ul style="list-style-type: none"> • Condition increasing likelihood of serious adverse reaction • Vaccines typically not given³
Precaution (Prec'n)	<ul style="list-style-type: none"> • Condition that might increase likelihood or severity of adverse reaction • Defer vaccine³
Adverse Event (AE)	<ul style="list-style-type: none"> • Untoward effect of vaccine or administration typically not causally related
Adverse Reaction (AR)	<ul style="list-style-type: none"> • Untoward effect of vaccine that are related to the vaccine

44

Diphtheria/Tetanus/Pertussis--CI, Precautions, AE, AR³

CI	<ul style="list-style-type: none"> • History of severe allergic reaction/ anaphylaxis
Prec'n	<ul style="list-style-type: none"> • Moderate or severe acute illness • Neurological condition, high temp, collapse or shock-like state, persistent inconsolable crying, convulsions, GBS, Arthus reaction
AE	<ul style="list-style-type: none"> • Severe systemic reactions: urticaria, anaphylaxis, neurological complications, GBS
AR	<ul style="list-style-type: none"> • Injection site reaction, mild systemic reactions, severe systemic reactions, extensive limb swelling, hives, anaphylaxis, neurological complications

45

Diphtheria/Tetanus/Pertussis--Other Notes

- "No study has assessed the safety of repeated doses of Tdap in pregnant women. CDC will monitor and assess the safety of Tdap use during pregnancy."³

46

Diphtheria/Tetanus/Pertussis--Other Notes

- Evolution of pertussis virus
 - "Epidemiology of pertussis has changed in recent years, with an increasing burden of disease among fully-vaccinated children and adolescents, which is likely being driven by transition to acellular vaccines in the 1990s"³
 - Vaccine-resistant strains emerging^{5, p. 87-99}
 - Greater number of whooping cough in vaccinated than unvaccinated children^{5, p. 102}
 - Vaccinated individuals can still spread disease^{5, p. 104}
 - Different strains
 - Declining immunity^{5, p. 88}

47

Diphtheria/Tetanus/Pertussis--Components³

- DT—aluminum phosphate, isotonic sodium chloride, formaldehyde
- DTaP (1)—aluminum phosphate, formaldehyde, glutaraldehyde, 2-phenoxyethanol
- DTaP (2)—formaldehyde, aluminum hydroxide, sodium chloride, polysorbate 80 (Tween 80)
- DTaP-IPV (1)—Formaldehyde, aluminum hydroxide, sodium chloride, polysorbate 80 (Tween 80), neomycin sulfate, polymyxin B
- DTaP-IPV (2)—formaldehyde, aluminum phosphate, 2-phenoxyethanol, polysorbate 80, glutaraldehyde, neomycin, polymyxin B sulfate, bovine serum albumin
- DTaP-HepB-IPV—formaldehyde, aluminum hydroxide, aluminum phosphate, sodium chloride, polysorbate 80 (Tween 80), neomycin sulfate, polymyxin B, yeast protein
- DTaP-IPV/Hib—aluminum phosphate, polysorbate 80, sucrose, formaldehyde, glutaraldehyde, bovine serum albumin, 2-phenoxyethanol, neomycin, polymyxin B sulfate

48

Haemophilus Influenzae Type B--Vaccine³

- *Haemophilus influenzae* type B (Hib)
 - Several manufacturers
- Also available as combination
 - Diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and Hib (DTaP-IPV/Hib)

49

Haemophilus Influenzae Type B--Schedule³

- 2 or 3 dose series depending on product used
 - 2, 4, +/- 6 months
- Booster at 12-15 months

50

Haemophilus Influenzae Type B--CI, Precautions, AE, AR³

CI	<ul style="list-style-type: none">• History of severe allergic reaction/anaphylaxis• Age younger than 6 weeks of age
Prec'n	<ul style="list-style-type: none">• Moderate or severe acute illness
AR	<ul style="list-style-type: none">• Injection site reaction, systemic and serious reactions not common

51

Haemophilus Influenzae Type B--Other Notes

- Vaccination against Hib has decreased cases of b strain, but increased cases caused by a strain (Hia) and non-typeable strains ^{3, p. 114-118}

52

Haemophilus Influenzae Type--Components³

- DTaP-IPV/Hib-aluminum phosphate, polysorbate 80, sucrose, formaldehyde, glutaraldehyde, bovine serum albumin, 2-phenoxyethanol, neomycin, polymyxin B sulfate
- Hib (1)-sodium chloride, formaldehyde, sucrose
- Hib (2) -formaldehyde, sodium chloride, lactose
- Hib (3)-amorphous aluminum hydroxyphosphate sulfate, sodium chloride

53

Hepatitis A--Vaccine³

- Hepatitis A (Hep A)
 - Several manufacturers
- Also available as combination with hepatitis A and hepatitis B

54

Hepatitis A--Schedule³

- 2 doses at ages 1-18 years
 - 1 year and 6-12 or 6-18 months later depending on manufacturer

55

Hepatitis A--CI, Precautions, AE, AR

CI	<ul style="list-style-type: none">• History of severe allergic reaction/ anaphylaxis• Allergy to aluminum or 2-phenoxyethanol³
Prec'n	<ul style="list-style-type: none">• Moderate or severe acute illness³
AE	<ul style="list-style-type: none">• Immune thrombocytopenia purpura (ITP)^{5, p. 208}
AR	<ul style="list-style-type: none">• Injection site reaction• No serious adverse reactions have been reported³

56

Hepatitis A--Components³

- Hep A (1)-MRC-5 cellular proteins, formalin, aluminum hydroxide, amino acid supplement, phosphate- buffered saline solution, polysorbate 20, neomycin sulfate, aminoglycoside antibiotic
- Hep A (2)-amorphous aluminum hydroxyphosphate sulfate, non-viral protein, DNA, bovine albumin, formaldehyde, neomycin, sodium borate, sodium chloride, other process chemical residuals
- Hep A/Hep B-MRC-5 human diploid cells, formalin, aluminum phosphate, aluminum hydroxide, amino acids, sodium chloride, phosphate buffer, polysorbate 20, neomycin sulfate, yeast protein, water

57

Hepatitis B--Vaccine³

- Hepatitis B (Hep B)
 - Several manufacturers
- Available as combination hepatitis A and hepatitis B

58

Hepatitis B--Schedule ³

- 3 doses at day 0 (birth), 1-2 months, 6-18 months
- Recommended for all under 18 years
- For unvaccinated adults only if at risk
 - Sexual exposure
 - Percutaneous or mucosal exposure to blood
 - Travel to areas with intermediate or high hepatitis B infection

59

Hepatitis B--CI, Precautions, AE, AR³

CI	<ul style="list-style-type: none">• History of severe allergic reaction/ anaphylaxis• Hypersensitivity to yeast or other vaccine component
Prec'n	<ul style="list-style-type: none">• Moderate or severe acute illness• Neurological condition, high temp, collapse or shock-like state, persistent inconsolable crying, convulsions, GBS, Arthus reaction
AE	<ul style="list-style-type: none">• Alopecia (rare), GBS, chronic fatigue syndrome, neurologic disorders, rheumatoid arthritis, type 1 diabetes, autoimmune disease
AR	<ul style="list-style-type: none">• Anaphylaxis

60

Hepatitis B--Other Notes

- No reliable data for blood brain barrier development in neonates and infants less than 4 months of age^{7a, 7b}

61

Hepatitis B--Components³

- Hep B (1)-aluminum hydroxide, yeast protein, sodium chloride, disodium phosphate dihydrate, sodium dihydrogen phosphate dihydrate
- Hep B (2)-formaldehyde, potassium aluminum sulfate, amorphous aluminum hydroxyphosphate sulfate, yeast protein
- Hep B (3)-yeast protein, yeast DNA, deoxycholate, phosphorothioate linked oligodeoxynucleotide, sodium phosphate, dibasic dodecahydrate, sodium chloride, monobasic dehydrate, polysorbate 80
- Hep A/Hep B-MRC-5 human diploid cells, formalin, aluminum phosphate, aluminum hydroxide, amino acids, sodium chloride, phosphate buffer, polysorbate 20, neomycin sulfate, yeast protein, water

62

Human Papillomavirus--Vaccine³

- Bivalent human papillomavirus (HPV2)
- Quadrivalent human papillomavirus (HPV4)
- 9-valent human papillomavirus (9vHPV)

63

Human Papillomavirus--Schedule³

- Female
 - HPV2, HPV4, 9vHPV 13-26 years
 - If begun at age 9-14 years: 2 dose series at 6-12 months apart
 - If begun age 15 or older: 3 dose series 0, 1-2 months, 6 months
- Male
 - HPV4 or 9vHPV 13-21 years
 - If begun at age 9-14 years: 2 dose series at 6-12 months apart
 - If begun age 15 or older: 3 dose series 0, 1-2 months, 6 months

64

Human Papillomavirus--CI, Precautions, AE, AR³

CI	<ul style="list-style-type: none"> • History of severe allergic reaction/ anaphylaxis • HPV2: allergy to latex³
Prec'n	<ul style="list-style-type: none"> • Moderate or severe acute illness • Not recommended during pregnancy³
AE	<ul style="list-style-type: none"> • Lupus, alopecia, gastroenteritis, vasculitis, GBS, thrombocytopenia⁵
AR	<ul style="list-style-type: none"> • Injection site reaction, fever, syncope for adolescents, nausea, dizziness, myalgia, malaise³

65

Human Papillomavirus--Other Notes³

- Females: bi- or quadrivalent; males: quadrivalent only
- CAN vaccinate if already infected
- 30% of cervical cancers caused by HPV types not included in vaccines
- Most cases and deaths from cervical cancer can be prevented through routine Pap test
- High incidence of infection, most resolve spontaneously

66

Human Papillomavirus--Components³

- amorphous aluminum hydroxyphosphate sulfate, sodium chloride, L-histidine, polysorbate 80, sodium borate, yeast protein

67

Influenza--Vaccine³

- Live attenuated influenza vaccine (LAIV)
 - Several manufacturers
- Inactivated influenza vaccine (IIV)
 - Trivalent or quadrivalent
 - Several manufacturers

68

Influenza--Schedule³

- Annual vaccination for all 6 months of age and older
- 2 doses 28 days apart for 1st round for children 6 months-8 years
 - 1 dose annually thereafter
- Live vaccine (LAIV)
 - 2-49 years
 - Not recommended for pregnant women
- Inactivated vaccine (IIV)
 - All persons 6 months of age and older

69

Influenza IIV--CI, Precautions, AE, AR³

CI	<ul style="list-style-type: none"> • History of severe allergic reaction/ anaphylaxis
Prec'n	<ul style="list-style-type: none"> • Moderate or severe acute illness • GBS within 6 weeks following influenza vaccine
AR	<ul style="list-style-type: none"> • Injection site reaction • Hypersensitivity reaction

70

Influenza LIAV--CI, Precautions, AE, AR³

CI	<ul style="list-style-type: none"> • History of severe allergic reaction/ anaphylaxis • Age younger than 2 or older than 50 • Several chronic medical conditions • Severe egg allergy • Children/adolescents on aspirin therapy • Immunosuppression • Pregnancy
Prec'n	<ul style="list-style-type: none"> • Moderate or severe acute illness • GBS within 6 weeks following a previous dose of influenza vaccine
AE	<ul style="list-style-type: none"> • Runny nose, headache, malaise
AR	<ul style="list-style-type: none"> • Wheezing in children 6-23 months • Cough, runny nose, nasal congestion, sore throat, chills

71

Influenza--Other Notes³

- Inactivated vaccine approximately 60% effective in protecting people less than 65 years old, less effective in those 65 and older
 - Though not highly effective in preventing illness, is 50-60% effective in preventing hospitalization and 80% effective at preventing death from influenza³
- Live vaccine about 87% effective in children 60-84 months
 - Only data reported by CDC

72

Influenza--Other Notes

- Studies point to problems with yearly flu vaccine
 - Natural infection with influenza A provides protection against more lethal influenza A viruses of other unrelated subtypes⁵, p.65
 - Meta analysis of epidemiologic studies as well as studies of active duty military following H1N1 pandemic showed that recipients of the 2008-2009 influenza trivalent vaccine significantly increased the risk of requiring medical attention for H1N1 pandemic virus⁵, p.66
 - Adults vaccinated 2 years in a row were as likely to get the flu as those not vaccinated either year⁵, p.69
 - Vaccination 2 years in a row was a risk factor for getting the flu⁵, p.69

73

Influenza--Components³

- Influenza (1) Trivalent & Quadrivalent--sodium chloride, monobasic sodium phosphate, dibasic sodium phosphate, monobasic potassium phosphate, potassium chloride, calcium chloride, sodium taurodeoxycholate, ovalbumin, sucrose, neomycin sulfate, polymyxin B, beta-propiolactone, thimerosal (multi-dose vials)
- Influenza (2)--squalene, polysorbate 80, sorbitan trioleate, sodium citrate dehydrate, citric acid monohydrate, neomycin, kanamycin, barium, hydrocortisone, egg proteins, cetyltrimethylammonium bromide (CTAB), formaldehyde
- Influenza (3) Quadrivalent--octoxynol-10 (TRITON X-100), α -tocopheryl hydrogen succinate, polysorbate 80 (Tween 80), hydrocortisone, gentamicin sulfate, ovalbumin, formaldehyde, sodium deoxycholate, sodium phosphate-buffered isotonic sodium chloride
- Influenza (4) Quadrivalent--sodium chloride, monobasic sodium phosphate, dibasic sodium phosphate, polysorbate 20 (Tween 20), baculovirus and Spodoptera frugiperda cell proteins, baculovirus and cellular DNA, Triton X-100

74

Influenza--Components³

- Influenza (5) Quadrivalent--Madin Darby Canine Kidney (MDCK) cell protein, phosphate buffered saline, protein other than HA, MDCK cell DNA, polysorbate 80, cetyltrimethylammonium bromide, and β -propiolactone, Thimerosal (multi-dose vials)
- Influenza (6) Quadrivalent--ovalbumin, formaldehyde, sodium deoxycholate, α -tocopheryl hydrogen succinate, polysorbate 80, thimerosal (multi-dose vials), phosphate-buffered saline solution
- Influenza (7) Quadrivalent--formaldehyde, egg protein, octylphenol ethoxylate (Triton X-100), sodium phosphate- buffered isotonic sodium chloride solution, thimerosal (multi-dose vials)
- Influenza (8) High Dose--egg protein, octylphenol ethoxylate (Triton X-100), sodium phosphate-buffered isotonic sodium chloride solution, formaldehyde
- Influenza (9) Quadrivalent--monosodium glutamate, hydrolyzed porcine gelatin, arginine, sucrose, dibasic potassium phosphate, monobasic potassium phosphate, ovalbumin, gentamicin sulfate, ethylenediaminetetraacetic acid (EDTA)

75

Measles/Mumps/Rubella--Vaccine³

- *Inactivated measles withdrawn in 1967*
- *Live attenuated measles withdrawn in 1975*
- *Further attenuated measles strain introduced in 1965 no longer used in US*
- Measles, mumps, rubella (MMR)
- Also available as measles, mumps, rubella with varicella (MMRV)

76

Measles/Mumps/Rubella--Schedule³

- 2 dose at 1st birthday (12-47 months) and 2nd dose at 4-6 years

77

Measles/Mumps/Rubella--CI, Precautions, AE, AR

CI	<ul style="list-style-type: none">• History of severe allergic reaction/ anaphylaxis including neomycin• Pregnancy (avoid for 4 weeks following)• Immunosuppression• Age >13 years³
Prec'n	<ul style="list-style-type: none">• Moderate or severe acute illness• Receipt of blood products, history of thrombocytopenia, personal or family history of seizures (MMRV)³
AE	<ul style="list-style-type: none">• Arthralgia (adult women), allergic reaction (rash, pruritus, purpura),³ thrombocytopenia⁵, p. 263-274
AR	<ul style="list-style-type: none">• Fever, febrile seizure, rash, orchitis, CNS dysfunction (deafness), aseptic meningitis, encephalitis⁵

78

Measles/Mumps/Rubella--Other Notes³

- Sterility, diabetes, deafness following the mumps—MYTH
 - "Sterility from mumps orchitis, even bilateral orchitis occurred infrequently...oophoritis rates were 1% or lower...There is no relationship to impaired fertility"
 - Aseptic meningitis resolves without sequelae in 3-10 days
 - "Incidence of mumps encephalitis is reported to range from 1 in 6,000 mumps cases (0.02%) to 1 in 300 mumps cases (0.3%)"
 - "Pancreatitis is infrequent...hyperglycemia is transient and reversible"
 - "Permanent unilateral deafness caused by mumps occurred in 1 of 20,000 infected persons; bilateral, severe hearing loss was very rare"

79

Measles/Mumps/Rubella--Other Notes³

- Does mumps vaccine confer immunity?
 - 2009 mumps outbreak
 - 90% had received 1 dose of MMR and 76% had received 2 doses
 - 2009-2010 mumps outbreak in Guam
 - Schools with most mumps cases had 99.3-100% coverage with 2 doses of MMR
- 2 dose mumps vaccine is 66%-95% effective

80

Measles/Mumps/Rubella--Components³

- MMR—vitamins, amino acids, fetal bovine serum, sucrose, glutamate, recombinant human albumin, neomycin, sorbitol, hydrolyzed gelatin, sodium phosphate, sodium chloride
- MMRV (Frozen: Recombinant Albumin)—MRC-5 cells including DNA and protein, sucrose, hydrolyzed gelatin, sodium chloride, sorbitol, monosodium L-glutamate, sodium phosphate dibasic, recombinant human albumin, sodium bicarbonate, potassium phosphate monobasic, potassium chloride; potassium phosphate dibasic, neomycin, bovine calf serum
- MMRV (Frozen: Human Serum Albumin)—MRC-5 cells including DNA and protein, sucrose, hydrolyzed gelatin, sodium chloride, sorbitol, monosodium L-glutamate, sodium phosphate dibasic, human albumin, sodium bicarbonate, potassium phosphate monobasic, potassium chloride; potassium phosphate dibasic, neomycin, bovine calf serum
- MMRV (Refrigerator Stable)—MRC-5 cells including DNA and protein, sucrose, hydrolyzed gelatin, urea, sodium chloride, sorbitol, monosodium L-glutamate, sodium phosphate, recombinant human albumin, sodium bicarbonate, potassium phosphate, potassium chloride, neomycin, bovine serum albumin

81

Meningococcal--Vaccine³

- Meningococcal polysaccharide vaccine (MPSV4)
 - Quadrivalent (A, C, W, Y)
- Meningococcal conjugate vaccine
 - Quadrivalent (A, C, W, Y)
 - MenACWY-D
 - MenACWY-CRM
- Meningococcal B
- Also available as combination with *Haemophilus influenzae* type B (Hib-MenCY-TT)
 - Bivalent (C, Y)

82

Meningococcal--Schedule³

- Meningococcal conjugate vaccine (MenACWY-D or MenACWY-CRM)
 - Age 11-12 years 1 dose
 - booster at 16 years
 - 1 dose only if over 16 years old
 - See Pink Book for special childhood populations
- No official recommendation for meningococcal B currently

83

Meningococcal Conjugate--CI, Precautions, AE, AR³

CI	<ul style="list-style-type: none">• History of severe allergic reaction/ anaphylaxis including diphtheria toxoid
Prec'n	<ul style="list-style-type: none">• Moderate or severe acute illness• GBS—removed by ACIP, remains in package insert
AE	<ul style="list-style-type: none">• Fever, headache, dizziness, syncope• 6.6% coded serious, 0.3-0.4% deaths reported• Injection site redness
AR	<ul style="list-style-type: none">• Injection site reaction

84

Meningococcal--Components

- Meningococcal (MenACWY 1)—sodium phosphate-buffered isotonic sodium chloride solution, formaldehyde, diphtheria toxoid
- Meningococcal (MenACWY 2)—formaldehyde, CRM197 protein
- Meningococcal (MenB 1)—aluminum hydroxide, sodium chloride, histidine, sucrose, kanamycin
- Meningococcal (MenB 2)—polysorbate 80, aluminum phosphate, histidine buffered saline²
- Haemophilus b meningococcal—aluminum hydroxyphosphate sulfate, sodium chloride⁸

85

Pneumococcal--Vaccine³

- Pneumococcal polysaccharide vaccine
 - 14-valent pneumococcal polysaccharide vaccine licensed in 1977
 - Replaced by 23-valent pneumococcal polysaccharide (PPSV23) in 1983
- Pneumococcal conjugate vaccine
 - 7-valent pneumococcal pneumococcal conjugate vaccine (PCV7) licensed in 2000
 - Replaced by 13-valent pneumococcal conjugate vaccine (PCV13) in 2010

86

Pneumococcal--Schedule³

- Childhood
 - 13-valent pneumococcal conjugate vaccine (PCV13)
 - 3 doses at 2, 4, 6 months of age
 - Booster at 12-15 months
- Adult
 - Age 65 and older
 - 1 dose PCV13 and 1 dose 23-valent pneumococcal polysaccharide (PPSV23)
- See Pink Book for additional recommendations for special and at-risk populations

87

Pneumococcal--CI, Precautions, AE, AR³

CI	<ul style="list-style-type: none">• History of severe allergic reaction/anaphylaxis
Prec'n	<ul style="list-style-type: none">• Moderate or severe acute illness• Safety in pregnancy not evaluated
AR	<ul style="list-style-type: none">• Injection site reaction, fever, decreased appetite, irritability

88

Pneumococcal--Other Notes³

- NOT “the pneumonia vaccine”
 - PCV13 approximately 45% effective in preventing pneumonia in adults, no data for children
 - PPSV23 60-70% effective in preventing invasive disease and “less effective in preventing pneumococcal pneumonia”
- PCV13-covered antigens responsible for
 - 61% of cases of invasive pneumococcal disease (IPD) in children
 - 20-25% IPD in adults 65 years and older
 - 10% community-acquired pneumonia
- PPSV23 contains antigen from 23 types of pneumococcal bacteria that cause 60-76% of invasive disease

89

Pneumococcal--Other Notes

- Strain replacement
 - Decreases in IPD seen after introduction of PCV7 were offset by IPD caused by serotypes not included
 - 2 years before introduction of PCV13, PCV7 strains causing less than 2% of IPD³
 - Strains targeted by PCV13 were reduced in healthy children 6-23 months old, but non-vaccine strains increased for all children
 - 2 years after PCV13 introduction, 94% of all pneumococcal strains in healthy children were non-vaccine targeted types^{5, p.125}

90

Pneumococcal--Components³

- Pneumococcal (PCV13)—CRM197 carrier protein, polysorbate 80, succinate buffer, aluminum phosphate
- Pneumococcal (PPSV-23)—phenol

91

Poliomyelitis--Vaccine³

- Oral live polio vaccine (OPV)
 - Not available in US since 2000
 - 95% of incidents of paralytic polio since 1980 caused by live oral vaccine
 - Last case reported in 2009
- Inactivated poliovirus vaccine (IPV)
 - Only polio vaccine available in US

92

Poliomyelitis--Schedule³

- Inactivated poliovirus vaccine (IPV)
 - 3 dose at 2, 4, 6 months old
 - Booster at 4-6 years
 - Not recommended for adults due to "very low risk of exposure to wild poliovirus"

93

Poliomyelitis--CI, Precautions, AE, AR³

CI	<ul style="list-style-type: none">• History of severe allergic reaction/ anaphylaxis
Prec'n	<ul style="list-style-type: none">• Moderate or severe acute illness
AR	<ul style="list-style-type: none">• Injection site reaction• Allergic reaction

94

Poliomyelitis--Other Notes

- Adverse reactions for combination vaccines are very different than monovalent vaccine
 - Not reported in Pink Book—not available in U.S.

95

Poliomyelitis--Components³

- Calf bovine serum albumin, 2-phenoxyethanol, formaldehyde, neomycin, streptomycin, polymyxin B, M-199 medium

96

Rotavirus--Vaccine³

- 1998 tetravalent rotavirus vaccine (RRV-TV)
 - Recommended for routine immunization of U.S. infants
 - Withdrawn from the market within the year
 - Association with intussusception
- Rotavirus 5 (RV5)
- Rotavirus 1 (RV1)

97

Rotavirus--Schedule³

- RV5
 - 3 oral doses at 2, 4, and 6 months
- RV1
 - 2 oral doses at 2 and 4 months
- Per CDC do not give to child older than 8 months
 - Per manufacturer maximum age RV5 32 weeks, RV1 24 weeks

98

Rotavirus--CI, Precautions, AE, AR³

CI	<ul style="list-style-type: none">• History of severe allergic reaction/ anaphylaxis• History of intussusception• Severe combined immunodeficiency• RV1: latex allergy
Prec'n	<ul style="list-style-type: none">• Moderate or severe acute illness• Moderate or severe acute gastroenteritis
AE	<ul style="list-style-type: none">• Intussusception still being studied
AR	<ul style="list-style-type: none">• Diarrhea, vomiting, otitis media, nasopharyngitis, bronchospasm, cough, runny nose, irritability

99

Rotavirus--Components³

- Rotavirus (RV5)-sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, fetal bovine serum [DNA from porcine circoviruses (PCV) 1 and 2 has been detected in RotaTeq. PCV-1 and PCV-2 are not known to cause disease in humans.]
- Rotavirus (RV1)-Dextran, Dulbecco's Modified Eagle Medium (sodium chloride, potassium chloride, magnesium sulfate, ferric (III) nitrate, sodium phosphate, sodium pyruvate, D-glucose, concentrated vitamin solution, L-cystine, L-tyrosine, amino acids, L-glutamine, calcium chloride, sodium hydrogenocarbonate, and phenol red), sorbitol, sucrose, calcium carbonate, sterile water, xanthan [Porcine circovirus type 1 (PCV-1) is present in Rotarix. PCV-1 is not known to cause disease in humans.]

100

Varicella--Vaccine³

- Varicella vaccine
 - Also available as measles/mumps/rubella/varicella vaccine
- Herpes zoster vaccine

101

Varicella--Schedule³

- Varicella
 - 2 doses at 12-15 months then 4-6 years
 - Plus any adolescent or adult without evidence of varicella immunity
- Herpes zoster
 - Single dose at age 60 or older

102

Varicella--CI, Precautions, AE, AR³

CI	<ul style="list-style-type: none">• History of severe allergic reaction/ anaphylaxis• Immunosuppression• Pregnancy/attempting to become pregnant
Prec'n	<ul style="list-style-type: none">• Moderate or severe acute illness• Receipt of blood products• Personal or family history of seizures• Avoid use of salicylates for 6 weeks after vaccination
AR	<ul style="list-style-type: none">• Injection site reaction• Varicella-like rash• Zoster caused by vaccine• MMRV: febrile seizure

103

Herpes Zoster--CI, Precautions, AE, AR³

CI	<ul style="list-style-type: none">• History of severe allergic reaction/ anaphylaxis• Immunosuppression• Pregnancy/attempting to become pregnant
Prec'n	<ul style="list-style-type: none">• Moderate or severe acute illness• Receipt of recombinant human immune mediators and modulators• Current treatment with antiviral drugs active against herpesviruses
AR	<ul style="list-style-type: none">• Injection site reaction

104

Varicella--Other Notes

- Vaccinating against chickenpox increases risk of shingles in teenagers and adults^{3, 5, p. 153-160}
- Some studies showing vaccinated children still contract chicken pox
 - Did not have milder symptoms than unvaccinated children^{5, p. 161}

105

Varicella--Components³

- Varicella Frozen—MRC-5 human diploid cells, including DNA & protein, sucrose, hydrolyzed gelatin, sodium chloride, monosodium L-glutamate, sodium phosphate dibasic, sodium phosphate monobasic, potassium phosphate monobasic, potassium chloride, EDTA, neomycin, fetal bovine serum
- Varicella Refrigerator Stable—MRC-5 human diploid cells, including DNA & protein, sucrose, hydrolyzed gelatin, sodium chloride, monosodium L-glutamate, urea, sodium phosphate dibasic, potassium phosphate monobasic, potassium chloride, neomycin, bovine calf serum
- Zoster Frozen—MRC-5 human diploid cells, including DNA & protein, sucrose, hydrolyzed porcine gelatin, sodium chloride, monosodium L-glutamate, sodium phosphate dibasic, potassium phosphate monobasic, potassium chloride; neomycin, bovine calf serum
- Zoster Refrigerator Stable—MRC-5 human diploid cells, including DNA & protein, sucrose, hydrolyzed porcine gelatin, urea, sodium chloride, monosodium L-glutamate, sodium phosphate dibasic, potassium phosphate monobasic, potassium chloride, neomycin, bovine calf serum

106



WHAT WAS THE MOST COMMON
CI?
PRECAUTION?
ADVERSE REACTION?

107

More Vaccine Schedules

- See CDC Pink Book or website for more information
 - Special populations
 - Catch up schedules
 - Vaccines for travel
 - Vaccines for military

108

Vaccine Components

109

What's In It?

- CDC
 - Pink Book or website
- Package inserts
 - <https://dailymed.nlm.nih.gov/dailymed/>

110

Vaccine Components—General Categories

<p>Adjuvant—Stimulate immune response</p> <ul style="list-style-type: none">• Aluminum salts including aluminum hydroxide, phosphate, and potassium aluminum sulfate of a mix of salts¹• Squalene—derived from shark liver¹⁰• Diphtheria toxoid³
<p>Antibiotics—Prevent microbial contamination from biological growth medium</p> <ul style="list-style-type: none">• Neomycin, polymyxin B, streptomycin, gentamicin⁹
<p>Formaldehyde—Inactivate viruses or bacterial toxins</p> <ul style="list-style-type: none">• Produced by the body• Present in vaccines in residual amounts⁴

111

Vaccine Components—General Categories⁹

Stabilizers

- Sugars—sucrose, lactose
- Amino acids—glycine, monosodium glutamate, trace amounts of human and bovine serum proteins

Growth Medium—For viral antigen

- Human, monkey, dog, and bovine DNA, cell parts, serum, albumin; baker's yeast; chicken eggs
- Trace amounts still present and listed on package insert

Preservatives—Inhibit bacterial growth for multi-dose vials

- Thimerosal

112

Components Explained

- Aluminum
 - Adjuvant
 - No known biochemical reaction requires aluminum and deleterious effects have been studied¹¹
 - What does the FDA say?
 - "the benefits of aluminum-containing vaccines administered during the first year of life outweigh any theoretical concerns about the potential effect of aluminum on infants. Of note, the most common source of exposure to aluminum is from eating food or drinking water"
 - Also, though, "When evaluating a vaccine for safety and efficacy, FDA considers adjuvants as a component of the vaccine; they are not licensed separately"⁹

113

Components Explained

- Aluminum cont'd
 - Injecting aluminum bypasses gastrointestinal tract
 - Changes pharmacodynamics
 - Many have continuous exposure in daily life
 - Vaccines may be small fraction
 - Antiperspirant, cookware/food storage, food sources (baking powder, food preservatives, food dye), pharmaceuticals¹¹

114

Components Explained³

- Vaccines containing aluminum
 - All tetanus and diphtheria
 - 1 manufacturer's *Haemophilus influenzae* type B
- Hepatitis A
- Hepatitis B
- 9-valent human papilloma virus
- All meningococcal
- Pneumococcal conjugate
- Other less commonly used vaccines (anthrax, Japanese encephalitis)

115

Components Explained³

- Antibiotics
 - Inhibit growth of bacteria from biological growth medium
- Vaccines containing antibiotics
 - Neomycin
 - Most diphtheria/tetanus containing vaccines
 - Hepatitis A
 - Varicella
 - Zoster
 - Other less commonly used (rabies, yellow fever etc)

116

Components Explained³

- Antibiotics cont'd
 - Polymyxin
 - Most diphtheria/tetanus containing vaccines
 - Inactivated poliovirus vaccine
 - Streptomycin
 - Inactivated poliovirus vaccine
 - Gentamicin
 - 2 manufacturers' quadrivalent influenza vaccines

117

Components Explained³

- Formaldehyde
 - Inactivate virus
 - Detoxify bacterial toxin
- Vaccines containing formaldehyde
 - All tetanus containing vaccines
 - 2 manufacturer's *Haemophilus influenzae* type B
 - 1 manufacturer's hepatitis B
 - Most influenza
 - Meningococcal conjugate
 - Other less commonly used (typhoid, anthrax)

118

Components Explained³

- Growth medium
 - Used to grow antigen-containing virus
 - Not completely removed during manufacturing
 - Listed as ingredient in package insert and on CDC
- Vaccines containing residual growth medium
 - Baker's yeast—hepatitis B
 - Chicken egg—live attenuated influenza

119

Components Explained³

- Growth medium cont'd
 - Madin Darby Canine Kidney (MDCK)—1 manufacturer's trivalent inactivated influenza
 - Chick embryo fibroblast—all measles and mumps containing vaccines
 - Monkey kidney tissue culture (Vero cell line)—1 manufacturer's inactivate poliovirus
 - Fetal bovine serum—rotavirus, varicella, 2 manufacturers' zoster

120

Components Explained³

- Growth medium cont'd
 - Calf serum albumin—inactivated poliovirus
 - Human albumin—measles, other less commonly used vaccines (small pox, rabies)

121

Components Explained

- Growth medium cont'd
 - Human diploid fibroblasts
 - MRC-5 Cell line from lung fibroblasts from fetus aborted in 1964^{12, 13}
 - Vaccines containing MRC-5
 - Hepatitis A
 - All rubella containing vaccines
 - 1 manufacturer's inactivated poliovirus
 - Varicella
 - Zoster³

122

Components Explained

- Thimerosal
 - Ethyl mercury containing compound
 - 49.6% mercury by weight¹³
 - Preservative to inhibit bacterial growth for multi-dose vials
 - Public Health Service and American Academy of Pediatrics recommended it be discontinued in 1999
 - 2003 was last expiration date of thimerosal containing childhood vaccine¹⁴
 - Still used in multi-dose flu vaccines³

123

Components Explained

• Thimerosal Con't

- "Compared to CDC's pre-2000 recommended vaccination schedule, the maximum lifetime exposure to thimerosal from vaccines has actually increased"^{5, p. 41}

Thimerosal	Influenza	FluShield	Wyeth	0.025 mg
	Influenza	Fluzone	Aventis Pasteur	0.025 mg
	Diphtheria-tetanus	DT (pediatric)	Aventis Pasteur	0.025 mg
	Pneumococcal polysaccharide	Pne-Immune 23	Wyeth	0.05 mg
	Meningococcal	Menomune	Aventis Pasteur	0.025 mg
	Japanese encephalitis virus	JE-Vax	Aventis Pasteur	0.007 mg

<https://pediatrics.aappublications.org/content/112/6/1394.long>

124

Components Explained

• Excipients common in products other than vaccines

- Monosodium Glutamate
- Sucrose, D-mannose, D-fructose, dextrose, anhydrous lactose, lactose, hydrolyzed casein
- sodium chloride, citric acid, sodium bicarbonate, sodium carbonate, phosphate buffered saline solution
- Glutaraldehyde
- amino acid supplement, asparagine, L-histidine
- Potassium phosphate, potassium, magnesium stearate, magnesium sulfate, ascorbic acid, potassium chloride, calcium chloride
- Microcrystalline cellulose, polysorbate 80 (Tween 80), polysorbate 20
- Cellulose acetate phthalate
- Alcohol, acetone, glycerin
- Castor oil
- FD&C Yellow #6 aluminum lake dye
- Sodium phosphate, Monobasic sodium phosphate, dibasic sodium phosphate, monobasic potassium phosphate, sodium citrate dehydrate
- hydrocortisone
- α -tocopheryl hydrogen succinate
- Ethylenediaminetetraacetic acid (EDTA), phenol, benzethonium chloride
- Sorbitan trioleate
- Disodium phosphate dihydrate


125

Components Explained

- All other excipients listed
- Plasdone C
- Polacrillin
- Iron ammonium citrate
- 2-phenoxyethanol
- Sodium borate
- Other process chemical residuals
- Deoxycholate
- Phosphorothioate linked oligodeoxynucleotide
- Dibasic dodecahydrate
- Monobasic dehydrate
- Sodium taurodeoxycholate
- Ovalbumin
- Beta-propiolactone
- Barium
- Cetyltrimethylammonium bromide (CTAB)
- Octoxynol-10 (TRITON X-100)
- Sodium deoxycholate
- Baculovirus and Spodoptera frugiperda cell proteins
- Baculovirus and cellular DNA
- Protein other than HA
- β -propiolactone
- CRM197 protein
- M-199 medium
- beta-propiolactone

126

Show What You Know



127

Helpful Resources for the Health Care Professional

- [CDC.gov](http://www.cdc.gov)
 - Official resource of vaccine information and a wealth of information
- Epidemiology and Prevention of Vaccine-Preventable Diseases "Pink Book"
 - Official vaccine handbook found on CDC.gov
- <http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm>
 - Official FDA roster of vaccines approved in the US
- <https://dailymed.nlm.nih.gov/dailymed/>
 - Repository of package inserts

128

What Every Practitioner Should Know About the Current Vaccination Campaign

Col. Arden Andersen, MSPH, PhD, DO
Hollie Resseguie, PharmD
hollie@obrienrx.com

129

References

1. Abbas, A.K., Lichtman, A.H. (2011). Basic immunology functions and disorders of the immune System. 3rd ed. Philadelphia, PA: Saunders.
2. Humphries S, Bystryanyk R *Dissolving Illusions: Disease, Vaccines, and the Forgotten History*.
3. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Hamborsky J, Kroger A, Wolfe S, eds. 13th ed. Washington D.C. Public Health Foundation, 2015.
4. Cowan, T. (2018). Vaccines, autoimmunity, and the changing nature of childhood illness. White River Junction, VT: Chelsea Green Publishing.

130

References

5. Miller, N.Z. (2016). Miller's review of critical vaccine studies: 400 Important scientific papers summarized for parents and researchers. Santa Fe, NM: New Atlantean Press.
6. Reviewed by Offit, P.Z. (2019). Vaccine History: Developments by year. Retrieved from <https://www.chop.edu/centers-programs/vaccine-education-center/vaccine-history/developments-by-year>
- 7a. Saunders, N.R., Liddelow, S.A., Dziegielewska, K. M. (2012). Barrier mechanisms in the developing brain. *Front Pharmacol*, 3 (46). doi: [10.3389/fphar.2012.00046](https://doi.org/10.3389/fphar.2012.00046).
- 7b. Webster, R. Blood brain barrier maturation: implication for drug development. Pfizer Global Research and Development. Retrieved from https://www.ema.europa.eu/documents/presentation/presentation-blood-brain-barrier-maturation-implications-drug-development_en.pdf

131

References

8. Haemophilus b conjugate (meningococcal protein conjugate). U.S. National Library of Medicine. Retrieved from <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dff46c6-4b15-4d10-aca6-d5ef3735a530>
9. Common ingredients in U.S. licensed vaccines. (2018). Food and Drug Administration. Retrieved from <https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/common-ingredients-us-licensed-vaccines>
10. Influenza A (H5N1) virus monovalent vaccine, adjuvanted, manufactured by ID Biomedical Corporation: Questions and answers. (2018). Food and Drug Administration. Retrieved from <https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/influenza-h5n1-virus-monovalent-vaccine-adjuvanted-manufactured-id-biomedical-corporation-questions#squalene>
11. Shaw, C.A., et al. (2014). Aluminum-induced entropy in biological systems: Implications for neurological disease. *Journal of Toxicology* (2014). <https://doi.org/10.1155/2014/491316>.

132

References

12. Sgreccia, E. Moral reflections on vaccines prepared from cells derived from aborted human fetuses. Retrieved from <https://www.immunize.org/talking-about-vaccines/vaticandocument.htm>
13. WI-38. ATCC. Retrieved from <http://www.atcc.org/products/all/CCL-75.aspx>
14. Understanding thimerosal, mercury, and vaccine safety. (2013). Centers for Disease Control and Prevention. Retrieved from <https://www.cdc.gov/vaccines/hcp/patient-ed/conversations/downloads/vacsafe-thimerosal-color-office.pdf>
15. Offit, P.A., Jew, R.K. Addressing parents' concerns: Do vaccines contain harmful preservatives, adjuvants, additives, or residuals? (2003). *American Academy of Pediatrics* (112)6. Retrieved from <https://pediatrics.aappublications.org/content/112/6/1394.long>
